Pharming Group NV (PHAR)

Pharming Group NV (PHAR) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $690M; returns 1 day +5.0%, 1 week +19.7%, 1 year -24.4%.

Pharming Group NV is a global biopharmaceutical company specializing in the development and commercialization of therapies for rare, debilitating, and life-threatening diseases. The company's revenue is primarily generated from two marketed products. The main revenue driver is RUCONEST® (recombinant human C1 esterase inhibitor), a treatment for acute attacks of Hereditary Angioedema (HAE).

Groups PHAR belongs to

• Biotechnology
• Biopharmaceutical
• Rare Diseases
• Healthcare
• Commercial Stage
• Pharmaceuticals
• Commercial Stage Biotech
• Life Sciences
• Immunotherapy
• Biologics

PHAR financial model: income statement, cash flow and balance sheet